EnGeneIC's cyto-immunotherapy technology uses non-living nano cells to release high concentrations of chemotherapeutic agents and RNA-interference molecules directly into targeted tumor cells, offering a potential new means for treating drug-resistant cancers. The company's drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo, and it serves customers in Australia, Singapore, Japan, and India.